PP
VRDN icon

PDT Partners’s Viridian Therapeutics VRDN Stock Holding History

PDT Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,475
Closed -$762K – 845
2024
Q3 		$762K Buy
+33,475
New +$547K 0.07% 421
2022
Q3 		– Sell
-10,114
Closed -$117K – 1109
2022
Q2 		$117K Sell
10,114
-4,276
-30% -$57.5K 0.01% 876
2022
Q1 		$266K Buy
14,390
+1,775
+14% +$34.1K 0.02% 744
2021
Q4 		$249K Buy
+12,615
New +$235K 0.02% 722

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

PDT Partners's VRDN Position: Q4 2024 in Review

PDT Partners sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 33,475 shares — an estimated $762K sold.

PDT Partners first reported a position in VRDN in Q4 2021 and held it in 4 quarters. The position peaked at $762K in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • PDT Partners reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 33,475 Viridian Therapeutics shares in Q4 2024, an estimated $762K.
  • PDT Partners first reported a position in Viridian Therapeutics in Q4 2021 and held it in 4 quarters.
  • PDT Partners's Viridian Therapeutics position peaked at $762K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.